reason report
upsid pt
bottom line holx improv reflect
revenue growth acceler level organ cc growth
increas y/i coupl increas cc
revenue growth guidanc revenue growth encourag
maintain mp rate revenue out-performance translat
ep upsid dont see lot rev/ep lever tap like
diagnost breast health divis bear brunt
growth acceler -- -impli less relianc improv
cyno gyn divis less optimist turnaround
potenti like confid sustain
msd growth breast health divis drove
out-performance qtr especi given tougher y/i comp year
progress pt increas vs prior appli slightli
higher price-to-earnings multipl vs prior -- heel recent grp multipl
expans ep
match pre-announce ep beat
consensu recal pre-announce revenue
rep cc management guidanc
rang beat consensu time organ
cc basi ex- blood screen bs faxitron/foc acq
growth upsid primarili driven breast health
bh lesser extent diagnost bh revenue
cc org ahead consensu strength
cc breast imag cc driven system sale
contribut softwar upgrad -- -help
acquisit faxitron focal diagnost revenue
cc org ahead consensu driven
continu momentum molecular cc -- -now three consecut
qtr growth acceler royalti -- -and larger
anticip contribut legaci blood screen busi
vs gyn revenue cc
consensu myosur deliv hsd growth off-set
novasur cont multi-qtr trend neg growth msd qtr
skelet revenue cc compar consensu
medic aesthet revenue cc
consensu weak bodi women
cc cc qtr respect partial off-set skin
cc gm consensu
street ebit margin came
consensu consensu in-
line tax rate lower share count vs think ultim led
ep beat vs consensu estim
medic suppli devic
ep
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rev/ep guid slightli street expect updat
report revenue guidanc narrow management increas lower
end rang vs prior
contempl addit fx headwind midpoint
full year bring cc revenue growth vs prior --
underscor expect continu oper strength
expect tax rate share translat new
adj ep rang vs prior step
beat midpoint management expect revenue
rang report
cc consensu management attribut sequenti
declin season weaker qtr diagnost gyn surgic
medic aesthet less bs revenue adj ep expect
rang think guidanc could prove conserv
given cont momentum key busi bh molecular could
potenti set anoth beat rais qtr howev neg market
dynam women health bodi caus uncertainti
guidanc reflect prudenc regard
like qtr improv cc org top-
line revenue growth mark second qtr row acceler revenue
growth impress growth bh organ cc driven
strong uptak mammographi system -- -and management
confid new product flow segment sustain steadier
predict revenue growth cadenc qtr year ahead
vs tradit lumpi capit sale cycl associ
segment on-going momentum molecular diagnost driven
contribut panther overal strategi chang
commun manag msd revenue growth achiev
sustain improv perform two largest
busi bh diagnost less relianc turnaround
cyno gyn -- -where less confid growth acceler
potenti actual see downsid risk
like least qtr part top-lin beat driven
legaci blood screen busi acquisit contd weak
medic aesthet women health franchis y/i declin
market remain weak follow fda cautionari letter
contd weak bodi franchis y/i declin due
competit dynam smaller privat compani take share
minim ep upsid vs consensu ep beat
guidanc rais despit sizeabl top-lin revenue beat -- -most revenue
upsid sourc lower margin area geographic/product
mix shift though benefit top-lin nice toward lower margin
model updat updat model come in-lin
revenue /ep guidanc model revenue /ep
cc org cc vs prior new
revenu in-lin revenue outlook reflect
y/y/ organ cc growth gm reduc vs prior
off-set slightli better opex control ep forecast
unchang contempl lower share count vs
prior revenue /ep estim y/i org cc
rate share market perform pt convict near-term ep estim
upsid diminish -- -especi tax-benefit- relat ep cushion
basic get use mitig reduc sale outlook lower cyno
expect cyno compani achil heel sinc acq close
begin question whether busi struggl might structur natur
vs pure sale forc execution/backfil management assum meanwhil still struggl
gyn franchis also turnaround time uncertain recent fda focu marketing/
indic women health product like monalisa touch add grow set headwinds/
uncertainti ultim view tough end-market rate stock mp pend
greater confid ep upsid potenti cyno number begin move
need come and/or organ cc revenue growth sustain move
back msd territori faster-than expect
price target vs prior base multipl appli ep
given improv underli perform driven bh out-performance improv
us molecular diagnost gyn think multipl continu expand depress
level close valuat gap peer current trade howev
still think discount group appropri given current slower top-lin profil
vs cyno busi challeng appli
get us appreci stock cheap price-to-earnings discount peer
price-to-earnings discount peer also think share could remain range-bound given
lower confid ep upsid potenti on-going under-perform segment
cyno especi near-term impact monalisa fda situat tempsur could
continu serv extend stock overhang limit near-term opportun multipl
peer group use blend select med-tech capit equipment/imag
comp group current trade averag forward price-to-earnings multipl
current trade ep
ev/ebitda basi trade peer group
average pt would impli ebitda
risk valuat includ us hospit administr pull back capital-expenditure
invest could caus delay holx capital-expos busi within breast health
tomo affirm unabl execut cost-synergi goal -- -or cyno integr
effort gener prove challeng expect -- -thi could make harder
achiev sale growth ep accret assumpt thu ep estim
enough increment growth tailwind off-set eventu slowdown beyond
tomo cycl could put out-year estim risk
dollar million except ep
svb leerink llc research streetaccount consensu compani report
dollar million except ep
margin sale
compani report svb leerink llc estim
organ cc growth
roughli in-lin cc
growth
headwind tailwind
geograph mix off-set
oper
improv cont
adopt new prod
throughout year
expens net
materi greater
growth
fx would also drag
fewer sell day
expect big
absorb declin
 hsd cc due
annual two eu
fx would also drag
fewer sell day
expect big
absorb declin
 hsd cc due
annual two eu
fx expect
organ cc growth
roughli in-lin cc
geograph mix off-set
growth
headwind tailwind
oper
improv cont
adopt new prod
organ cc growth low-
organ growth
ex-cyno ex-b
organ growth
greater
adj fewer sell day
non-recur
royalti revenue
expens net
materi greater
growth
expand faster
low mid singl digit
growth new
mammographi biopsi
bs expect coninu
low mid singl digit
surgic product
declin significantli
growth myosur
bs
larg servic annuiti
total well
panther fusion assay
 modest declin
novasur
low mid singl digit
growth affirm
brevera busi
bs expect declin
littl half revenue
growth improv
growth market
myosur stabil
novasur
low mid singl digit
growth stabil
product sale
forc tempsur
sale significantli
full-year revenue
materi vs
pro-forma
basi
expect grow y/i
declin
sequenti basi due
normal season
impact monalisa
adj non-gaap gross profit ex-amort
adj non-gaap incom oper ex-amort
incom incom tax
provis incom tax
adj non-gaap net incom ex-amort
adj non-gaap ep ex-amort dilut
compani report svb leerink llc estim
compani report svb leerink llc estim
